American journal of otolaryngology · 2025
Incidence and prognosis of otitis media with effusion in COVID-19 patients a comparative case-control analysis.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yu Qian, Zhang Yuedong, Lu Huina, Zhao Yanli, Zhou Xin
Аннотация
OBJECTIVE: To investigate the association between SARS-CoV-2 and secretory otitis media (OME), evaluating the presence of the virus in middle ear fluid (MEF) and its impact on OME incidence and patient outcomes.
METHODS: A case-control study was conducted with COVID-19 patients (n = 86) and control subjects (n = 20). OME incidence was compared across three time periods. Recovery rates, recurrence rates, catheterization rates, Eustachian Tube Dysfunction Questionnaire-7 (ETDQ-7) scores, as well as audiometry results were analyzed.
RESULTS: The detection of SARS-CoV-2 in MEF samples showed a similar duration compared to nasal swabs (28.65 ± 8.99 vs 27.18 ± 7.99 days). There was a significant increase in OME incidence following COVID-19 infection, particularly during the '22-'23 period (P < 0.05). No significant differences were observed in terms of recovery rates, recurrence rates or catheterization rates among groups (P > 0.05). ETDQ-7 scores remained unchanged after treatment intervention (P > 0.05). Statistically significant differences were found for air conduction threshold and air-bone gap measurements (P < 0.05).
CONCLUSION: The presence of SARS-CoV-2 in MEF is associated with an elevated risk of developing OME but has minimal impact on the prognosis of this condition.
METHODS: A case-control study was conducted with COVID-19 patients (n = 86) and control subjects (n = 20). OME incidence was compared across three time periods. Recovery rates, recurrence rates, catheterization rates, Eustachian Tube Dysfunction Questionnaire-7 (ETDQ-7) scores, as well as audiometry results were analyzed.
RESULTS: The detection of SARS-CoV-2 in MEF samples showed a similar duration compared to nasal swabs (28.65 ± 8.99 vs 27.18 ± 7.99 days). There was a significant increase in OME incidence following COVID-19 infection, particularly during the '22-'23 period (P < 0.05). No significant differences were observed in terms of recovery rates, recurrence rates or catheterization rates among groups (P > 0.05). ETDQ-7 scores remained unchanged after treatment intervention (P > 0.05). Statistically significant differences were found for air conduction threshold and air-bone gap measurements (P < 0.05).
CONCLUSION: The presence of SARS-CoV-2 in MEF is associated with an elevated risk of developing OME but has minimal impact on the prognosis of this condition.